Drug Trial Radar · NCT04069689
Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Aug 29, 2019
Primary completion
Nov 27, 2019
Study completion Nov 27, 2019
Sponsor
- Lead sponsor
- EpygenixIndustry
- Sponsor type
- Industry
- First posted
- Aug 28, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a placebo-controlled, double-blind, 2-period study in 3 sequential groups of 8 healthy subjects each. The safety and pharmacokinetics of escalating single and multiple oral doses of EPX-100 will be assessed in fasting healthy subjects and following a high-fat meal.
Conditions
- Dravet Syndrome
Interventions
EPX-100 (Clemizole Hydrochloride)Drug
EPX-100 (Clemizole Hydrochloride)
PlacebosDrug
Placebo to match EPX-100
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events (TEAEs)Time frame: 21 days
- Serial ECGs - QTcF IntervalTime frame: 21 days
- Physical Examinations Including Actual Body WeightTime frame: 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
TKL Research
Fair Lawn, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.